AstraZeneca inks drug development deal with Compugen

Apr 02, 2018

AstraZeneca has entered into a licensing deal with Israeli-based Compugen to make cancer treatments.

The companies said that under the agreement AstraZeneca’s research unit will develop engineered antibody products from Compugen’s drug oncology pipeline. Compugen is paying $100 million upfront for the deal, but could receive up to $200 million in royalties on the new treatments.

Compugen said the deal will help secure future research into cancer treatments.

Read the full Reuters report.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments